相关实验视频

Updated: Jun 26, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

对非酒精性脂肪性肝病GIPR激动剂的疗效评估:一个调解门德尔随机化研究

Siyuan Xie¹, Delong Chen², Yangke Cai¹

¹Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

|May 12, 2024

概括

葡萄糖依赖型胰岛素多受体激活剂 (GIPRAs) 在降低非酒精性脂肪肝 (NAFLD) 风险方面发挥了因果作用. 这种效应很可能是通过提高甘油三和HDL-C水平来调节的.

科学领域:

代谢性疾病研究研究.
肝病学肝病学是一种肝病学.
药物基因组学药物基因组学

背景情况:

非酒精性脂肪肝 (NAFLD) 是一个普遍存在的全球健康问题,缺乏向治疗.
新兴的治疗点包括调节葡萄糖代谢和相关途径的药物.

研究的目的:

调查依赖葡萄糖的胰岛素型多受体激活剂 (GIPRAs) 和NAFLD之间的因果关系.
确定GIPRA对NAFLD风险产生影响的潜在调解因素.

主要方法:

使用孟德尔的随机化 (MR) 与GIPRAs的遗传代理.
使用GIPR基因的cis-SNP与基因表达和HbA1c相关.
为了验证,进行了同位素化和链接不平衡分析.

主要成果:

基因代理GIPRAs证明了与NAFLD风险降低的显著因果关系 (OR:0.46).
吉普拉也与较低的2型糖尿病 (T2DM) 风险有因果关系 (OR:0.10).
调解分析表明,GIPRA对NAFLD通过改善甘油三 (TG) 和高密度胆固醇 (HDL-C) 的间接影响.

结论:

这项研究提供了强有力的证据,证明GIPRAs在减轻NAFLD风险方面的因果作用.
吉普拉对NAFLD的治疗效果似乎是由改善的脂质代谢,特别是TG和HDL-C水平的介导.
这些发现为未来的临床试验提供了宝贵的见解,研究基于GIPRA的NAFLD治疗方法.

关键词:

遗传流行病学遗传流行病学葡萄糖依赖的胰岛素型多受体受体.脂质蛋白是一种脂质蛋白.门德尔的随机化非酒精性脂肪性肝病是非酒精性脂肪性肝病.

更多相关视频

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Published on: September 9, 2021

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...